A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
EvolveImmune United, Inc
OncoC4, Inc.
Sotio Biotech Inc.
National Cancer Institute (NCI)